



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

... Under 37 C.F.R. 1.84 these drawings

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. 07/666,252 03/08/91 WALL $\mathbf{v}_{i}(t) = t_{i}(t)$ **EXAMINER** CATHRYN CAMPBELL PRETTY, SCHROEDER, BRUEGERMANN & CLARK 444 SOUTH FLOWER STREET WIE. 2000 ART UNIT PAPER NUMBER LOS ANGLES, CA 90071 13 1814 07/17/92 DATE MAILED: This is a communication from the examiner in charge of your application. COMMISSIONER OF PATENTS AND TRADEMARKS For the purpose of restriction

This application has been examined Responsive to communication filed on ______ This action is made final. Failure to respond within the period for response will cause the application to become abandoned. 35 U.S.C. 133 THE FOLLOWING ATTACHMENT(8) ARE PART OF THIS ACTION Part I 3. Notice of Art Cited by Applicant, PTO-1449. 4.

Notice of informal Patent Application, Form PTO-152. 5. Information on How to Effect Drawing Changes, PTO-1474. a. 🗆 Part II SUMMARY OF ACTION 1. 🛭 Claims __/- 59 are pending in the application. Of the above, claims __ are withdrawn from consideration. 2 Claims_ _ have been cancelled 3. Claims ___ are allowed. 4. Claims ___ 5. Claims ___ 6. B Claims_/- 59 are subject to restriction or election requirement. 7.

This application has been filed with informal drawings under 37 C.F.R. 1.85 which are acceptable for examination purposes.

EXAMINER'S ACTION

PTOL-326 (Rev. 9-89)

14. Other

The corrected or substitute drawings have been received on _____

examiner. \square disapproved by the examiner (see explanation).

are acceptable. not acceptable (see explanation or Notice re Patent Drawing, PTO-948).

been filed in parent application, serial no. _____; filed on _

accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.

10. The proposed additional or substitute sheet(s) of drawings, filed on ______ has (have) been approved by the

13.

Since this application appears to be in condition for allowance except for formal matters, prosecution as to the merits is closed in

12.

Acknowledgment is made of the claim for priority under U.S.C. 119. The certified copy has

been received

not been received

Serial Number 07/666,252 Art Unit 1814

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-18 and 29-41, drawn to a mammalian recombination system containing DNA wherein transformed host cells and non-human transgenic animals contain the DNA, and method of assembling functional genes are classified in Class 435, subclasses 320.1, 240.2, 172.3 and Class 536, subclass 27, and Class 800, subclass 2.
- II. Claims 19-23, drawn to a method of disrupting gene function so as to prevent inactivation of expression are classified in Class 435, subclass 172.3.
- III. Claim 24, drawn to obtaining DNA from the genome of a transfected organism containing tandemly oriented FLP target sites is for example classified in Class 435, subclass 91.
- IV. Claims 25-28 and 42-55, drawn to a method of precisely targeted integration of DNA in cells (claims 25-28 and 42-48) and non-human transgenic animals (claims 25-28 and 49-55) are for example classified in Class 435, subclass 172.3
- V. Claims 56 and 57, drawn to a method for analysis of mammalian development are classified in Class 435, subclass 4.
- VI. Claims 58 and 59, drawn to a cotransfection assay are classified in Class 435, subclass 6.

The inventions are distinct, each from the other because of the following reasons:

The inventions of Groups I and of II, IV, V, and VI are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP 806.05(h)). In the instant case, the DNA can be used as a probe as opposed to the process gene disruption disclosed in Group II or the gene targeting set forth in the claims of Group IV or in bioassays as in indicated in Groups V and VI wherein Groups II, IV, V, and VI are alternative processes of use.

Serial Number 07/666,252 Art Unit 1814

The inventions of Group III and I are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different products or (2) that the product as claimed can be made by another and materially different process (MPEP 806.05(f)). In the instant case, the DNA of Group I can apparently be obtained by the alternative process recited in the claims of Group III or by traditional chemical synthesis.

Because these inventions are distinct for the reasons given above and since they have acquired a separate status in the art as shown by their different classification, subject matter, and are separately and independently searched, restriction for examination purposes as indicated is proper.

A telephone conversation on 13 July with Steven E. Reiter did not result in an election being made.

Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(h).

An inquiry concerning this communication should be directed to Christopher Low at telephone number (703) 308-0196.

CSFL 15 July 1992 Christopher S.F. LOW
PATENT EXAMINER
GROUP 180